BioSpace News Archive

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, MD, the Company’s Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference.

The Columbus Organization, a leading provider of case management services for individuals with Intellectual and Developmental Disabilities, today announced the acquisition of Progressive Journey Group (PJG), a leading provider of support coordination for the Spanish speaking I/DD community in central Florida.

Health Enterprise Partners, a healthcare private equity firm, today announced it has taken the ParityPledge.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the availability of both commercial animal model production and colony management services through a new location in San Diego.

DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis.

Dr. Miles-Thomas joined Urology of Virginia in early 2014 as its first female urologist.

Companies that do not cease manufacture, distribution and sale of unauthorized flavored cartridge-based e-cigarettes within 30 days risk FDA enforcement actions

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco,

Ironwood Pharmaceuticals, Inc. will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 4:00 p.m. Pacific Time/ 7:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco.

Acura has also completed a non-clinical small animal study to identify the benefits of a reduction in peak plasma drug concentrations on opioid induced respiratory depression .